natgillin/translations-raw huggingface dataset:
In treatment of DVT with or without PE, patients receiving enoxaparin sodium were treated with either a 100 IU/kg (1 mg/kg) SC dose every 12 hours or a 150 IU/kg (1.5 mg/kg) SC dose once a day. 
(40 mg) subkutano enkrat na dan. Za zdravljenje GVT s PE ali brez nje so bili bolniki, ki so prejemali natrijev enoksaparinat, zdravljeni z odmerkom 100 i.e./kg (1 mg/kg) subkutano na 12 ur ali z odmerkom 150 i.e./kg (1,5 mg/kg) subkutano enkrat na dan.
This helps your body to break them down and stops them from causing you harm2) Stopping blood clots from forming in your blood. 
Tako telesu pomaga, da jih razgradi, in prepreči, da bi povzročili škodo
10,000 IU/mL (100 mg/mL) solution for injection: 
10.000 i.e./ml (100 mg/ml) raztopina za injiciranje:
Therefore, careful clinical monitoring is advised in these patients (see section 
Zato je treba te bolnike priporočljivo klinično nadzorovati (glejte poglavje 5.2).
8,000 IU (80 mg) /0.8 mL 
8.000 i.e. (80 mg) /0,8 ml
R 
D L
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PEN 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
• If you are using LOVENOX (and associated names) to treat blood clots in your body and going to receive spinal or epidural anaesthesia or lumbar puncture within 24 hours. 
• Če uporabljate LOVENOX (in povezana imena) za zdravljenje krvnih strdkov in imate v
Retroperitoneal haemorrhage 
Retroperitonealn a krvavitev
What LOVENOX (and associated names) looks like and contents of the pack 
Izgled zdravila LOVENOX (in povezana imena) in vsebina pakiranja
Method of administration LOVENOX (and associated names) should not be administered by the intramuscular route. 
Zdravila LOVENOX (in povezana imena) se ne sme injicirati intramuskularno.
Enoxaparin sodium is to be used with extreme caution in patients with a history (>100 days) of heparin-induced thrombocytopenia without circulating antibodies. 
Natrijev enoksaparinat je treba skrajno previdno uporabljati pri bolnikih z anamnezo (> 100 dni)
The usual dose is 100 IU (1 mg) for every kilogram of your weight. 
Običajen odmerek je 100 i.e. (1 mg) na kilogram telesne mase.
Your doctor will decide how much LOVENOX (and associated names) to give you. 
Zdravnik bo določil, koliko zdravila LOVENOX (in povezana imena) boste dobili.
o Initial 3,000 IU (30 mg) bolus 
o Začetni bolus 3.000 i.e. (30 mg)
Your doctor will request you perform blood tests called INR and tell you when to start LOVENOX (and associated names) accordingly. 
imenovano INR, in vam bo glede na to povedal, kdaj začnite uporabljati zdravilo LOVENOX (in povezana imena).
• For treatment of acute STEMI, the recommended dose of enoxaparin sodium is a single intravenous (IV) bolus of 3,000 IU (30 mg) plus a 100 IU/kg (1 mg/kg) SC dose followed by 100 IU/kg (1 mg/kg) administered SC every 12 hours (maximum 10,000 IU (100 mg) for each of the first two SC doses). 
• Za zdravljenje akutnega STEMI je priporočeni odmerek natrijevega enoksaparinata enkraten intravenski bolus 3.000 i.e. (30 mg) in 100 i.e./kg (1 mg/kg) subkutano, nato pa 100 i.e./kg
One vial contains enoxaparin sodium 50,000 IU anti-Xa activity (equivalent to 500 mg) + 75 mg benzyl alcohol in 5.0 mL water for injections. 
Ena viala vsebuje 50.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 500 mg) in 75 mg benzilalkohola v 5,0 ml vode za injekcije.
Multiple dose vials containing benzyl alcohol 
Večodmerne viale, ki vsebujejo benzilalkohol
Extracorporeal use (in the dialysis circuit). 
izventelesna uporaba (v dializnem obtoku)
At doses used for prophylaxis of venous thromboembolism, enoxaparin sodium does not influence bleeding time and global blood coagulation tests significantly, nor does it affect platelet aggregation or binding of fibrinogen to platelets. 
• Laboratorijske preiskave V odmerkih, uporabljanih za profilakso venske trombembolije, natrijev enoksaparinat ne vpliva pomembno na čas krvavitve in preiskave celotne koagulacije krvi.
If you get any side effects, talk to your doctor orpharmacist or nurse. 
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
What you need to know before you use LOVENOX (and associated names) 
Kaj morate vedeti, preden boste uporabili zdravilo LOVENOX (in povezana imena) Ne uporabljajte zdravila LOVENOX (in povezana imena)
When given at a dose of 4,000 IU (40 mg) once a day SC, enoxaparin sodium significantly reduced the incidence of VTE as compared to placebo. 
(40 mg) enkrat na dan subkutano je zmanjšal incidenco VTE značilno bolj kot placebo.
Treatment of unstable angina and non ST elevation myocardial infarction In a large multicenter study, 3,171 patients enrolled at the acute phase of unstable angina or non-Qwave myocardial infarction were randomized to receive in association with acetylsalicylic acid (100 to 325 mg once daily), either SC enoxaparin sodium 100 IU/kg (1 mg/kg) every 12 hours or IV unfractionated heparin adjusted based on aPTT. 
V veliki multicentrični študiji so 3.171 bolnikov, vključenih v akutni fazi nestabilne angine pektoris ali miokardnega infarkta brez zobca Q, randomizirali na prejemanje natrijevega enoksaparinata 100 i.e./kg (1 mg/kg) subkutano na 12 ur ali nefrakcioniranega heparina intravensko s prilagoditvijo glede na aPTČ.
• Your doctor will decide how much LOVENOX (and associated names) to give you. 
• Zdravnik bo določil, koliko zdravila LOVENOX (in povezana imena) boste dobili.
{MM/YYYY} {DD/MM/YYYY} {DD month YYYY} 
{Ime in naslov} {tel.} {faks}
A puncture-free interval of at least 12 hours shall be kept between the last injection of enoxaparin sodium at prophylactic doses and the needle or catheter placement. 
Med zadnjo injekcijo natrijevega enoksaparinata v profilaktičnih odmerkih in vstavitvijo igle ali katetra mora miniti vsaj 12 ur brez punkcij.
One vial contains enoxaparin sodium 100,000 IU anti-Xa activity (equivalent to 1000 mg) + 150 mg benzyl alcohol in 10.0 mL water for injections. 
Ena viala vsebuje 100.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 1000 mg) in 150 mg benzilalkohola v 10,0 ml vode za injekcije.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER BOX AMPOULE 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA ZA AMPULO
STATEMENT OF ACTIVE SUBSTANCE(S) One vial (10.0 mL) contains 10,000 IU (100 mg) enoxaparin sodium. 
Ena viala (10,0 ml) vsebuje 10.000 i.e. (100 mg) natrijevega enoksaparinata SEZNAM POMOŽNIH SNOVI
The incidence of major bleeding at 30 days was significantly higher (p<0.0001) in the enoxaparin sodium group (2.1%) versus the heparin group (1.4%). 
(2,1 %, p < 0,0001) kot v skupini s heparinom (1,4 %).
Initiate dosing with 75 IU/kg (0.75 mg/kg) SC every 12 hours (maximum 7,500 IU (75 mg) for each of the first two SC doses only, followed by 75 IU/kg (0.75 mg/kg) SC dosing for the remaining doses). 
i.e. (75 mg) za vsakega od prvih dveh subkutanih odmerkov, nato pa 75 i.e./kg (0,75 mg/kg) subkutano za preostale odmerke).
• LOVENOX (and associated names) can be added to the tube leaving the body (arterial line) at the start of the dialysis session. 
• Zdravilo LOVENOX (in povezana imena) se lahko na začetku dialize da v cevko, ki vodi iz telesa
Major bleeding were respectively 1.7% in the enoxaparin sodium 150 IU/kg (1.5 mg/kg) once a day group, 1.3% in the enoxaparin sodium 100 IU/kg (1 mg/kg) twice a day group and 2.1% in the heparin group. 
1,7 %, v skupini s 100 i.e./kg (1 mg/kg) natrijevega enoksaparinata dvakrat na dan 1,3 % in v skupini s heparinom 2,1 %.
What LOVENOX (and associated names) contains 
LOVENOX (in povezana imena).
A 3,000 IU (30 mg) IV bolus immediately followed by a 100 IU/kg (1 mg/kg) SC every 12 hours provided initial maximum anti-Xa activity level of 1.16 IU/mL (n=16) and average exposure corresponding to 88% of steady-state levels. 
12 ur, je dosegel uvodno največjo raven aktivnosti anti-Xa 1,16 i.e./ml (n = 16) in povprečno izpostavljenost, ki je ustrezala 88 % tiste v stanju dinamičnega ravnovesja.
Renal impairment (see sections 4.4 and 5.2) 
ki vplivajo na hemostazo (glejte poglavji 4.4 in 4.5).
These agents include medicinal products such as: 
• Druga zdravila, ki vplivajo na hemostazo, na primer:
Rare: 
Krvavitevα Redki:
- Changing from treatment with direct oral anticoagulant to LOVENOX (and associated names) Stop taking direct oral anticoagulant. 
- Prehod z zdravljenja z neposrednim peroralnim antikoagulansom na zdravilo LOVENOX (in povezana imena)
• Active clinically significant bleeding and conditions with a high risk of haemorrhage, including recent haemorrhagic stroke, gastrointestinal ulcer, presence of malignant neoplasm at high risk of bleeding, recent brain, spinal or ophthalmic surgery, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities; 
prisotnostjo maligne novotvorbe z velikim tveganjem za krvavitev, nedavno operacijo na možganih, hrbtnem mozgu ali očeh, znanimi varicami požiralnika ali sumom nanje,
• If you have any sign of blockage of a blood vessel by a blood clot such as : - cramping pain, redness, warmth, or swelling in one of your legs - these are symptoms of deep vein thrombosis - breathlessness, chest pain, fainting or coughing up blood - these are symptoms of a pulmonary embolism 
• Če imate kakršen koli znak zamašitve žile s krvnim strdkom, na primer: - krčevite bolečine, pordelost, toploto ali oteklost ene noge - to so simptomi globoke venske tromboze,
LOVENOX (and associated names) 30,000 IU (300 mg)/3 mL solution for injection LOVENOX (and associated names) 50,000 IU (500 mg)/5 mL solution for injection LOVENOX (and associated names) 100,000 IU (1,000 mg)/10 mL solution for injection 
LOVENOX (in povezana imena) 30.000 i.e. (300 mg)/3 ml raztopina za injiciranje LOVENOX (in povezana imena) 50.000 i.e. (500 mg)/5 ml raztopina za injiciranje LOVENOX (in povezana imena) 100.000 i.e. (1.000 mg)/10 ml raztopina za injiciranje
Do not use LOVENOX (and associated names) 
Nehajte jemati zdravilo LOVENOX (in povezana imena).
- Changing from blood thinners called vitamin-K antagonists (e.g. warfarin) to LOVENOX (and associated names) 
- Prehod s sredstev za redčenje krvi, imenovanih antagonisti vitamina K (npr. varfarin) na zdravilo
[To be completed nationally] [See Annex I - To be completed nationally] [For referral procedures] 
[Glejte Prilogo I - Izpolni država članica] [Za postopke predložitve, kot je ustrezno.]
Prophylaxis of venous thromboembolism in medical patients The recommended dose of enoxaparin sodium is 4,000 IU (40 mg) once daily by SC injection. 
Priporočeni odmerek natrijevega enoksaparinata je 4.000 i.e. (40 mg) enkrat na dan v subkutani injekciji.
One vial contains enoxaparin sodium 30,000 IU anti-Xa activity (equivalent to 300 mg) + 45 mg benzyl alcohol in 3.0 mL water for injections. 
Ena viala vsebuje 30.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 300 mg) in 45 mg benzilalkohola v 3,0 ml vode za injekcije.
LOVENOX (and associated names) 30,000 IU (300 mg) /3.0 mL solution for injection LOVENOX (and associated names) 50,000 IU (500 mg)/5.0 mL solution for injection LOVENOX (and associated names) 100,000 IU (1,000 mg)/10 mL solution for injection [See Annex I - To be completed nationally] 
LOVENOX (in povezana imena) 30.000 i.e. (300 mg)/3 ml raztopina za injiciranje LOVENOX (in povezana imena) 50.000 i.e. (500 mg)/5 ml raztopina za injiciranje LOVENOX (in povezana imena) 100.000 i.e. (1.000 mg)/10 ml raztopina za injiciranje [Glejte Prilogo I - Izpolni država članica]
One vial contains enoxaparin sodium 10,000 IU anti-Xa activity (equivalent to 100 mg) in 10 mL water for injections. 
Ena viala vsebuje 10.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 100 mg) v 10 ml vode za injekcije.
Each prefilled syringe contains enoxaparin sodium 12,000 IU anti-Xa activity (equivalent to 120 mg) in 0.8 mL water for injections. 
Ena napolnjena injekcijska brizga vsebuje 12.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 120 mg) v 0,8 ml vode za injekcije.
One pre-filled syringe (0.2 mL) contains 2,000 IU (20 mg) enoxaparin sodium One pre-filled syringe (0.4 mL) contains 4,000 IU (40 mg) enoxaparin sodium One pre-filled syringe (0.6 mL) contains 6,000 IU (60 mg) enoxaparin sodium One pre-filled syringe (0.8 mL) contains 8,000 IU (80 mg) enoxaparin sodium One pre-filled syringe (0.8 mL) contains 12,000 IU (120 mg) enoxaparin sodium One pre-filled syringe (1 mL) contains 10,000 IU (100 mg) enoxaparin sodium One pre-filled syringe (1 mL) contains 15,000 IU (150 mg) enoxaparin sodium 
Ena napolnjena injekcijska brizga (0,2 ml) vsebuje 2.000 i.e. (20 mg) natrijevega enoksaparinata Ena napolnjena injekcijska brizga (0,4 ml) vsebuje 4.000 i.e. (40 mg) natrijevega enoksaparinata Ena napolnjena injekcijska brizga (0,6 ml) vsebuje 6.000 i.e. (60 mg) natrijevega enoksaparinata Ena napolnjena injekcijska brizga (0,8 ml) vsebuje 8.000 i.e. (80 mg) natrijevega enoksaparinata Ena napolnjena injekcijska brizga (0,8 ml) vsebuje 12.000 i.e. (120 mg) natrijevega enoksaparinata Ena napolnjena injekcijska brizga (1 ml) vsebuje 10.000 i.e. (100 mg) natrijevega enoksaparinata Ena napolnjena injekcijska brizga (1 ml) vsebuje 15.000 i.e. (150 mg) natrijevega enoksaparinata
Pre-Filled Syringes: 
Napolnjene injekcijske brizge:
Other medicines and LOVENOX (and associated names) Tell your doctor or pharmacist if you are taking or might take/use any other medicines. 
Obvestite svojega zdravnika ali farmacevta, če uporabljate ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
No dose adjustment is recommended in patients with moderate (creatinine clearance 30-50 mL/min) and mild (creatinine clearance 50-80 mL/min) renal impairment. 
Pri bolnikih z zmerno (očistek kreatinina 30-50 ml/min) in blago (očistek kreatinina
Very common: Haemorrhage α Rare: 
Zelo pogosti: Krvavitevα
Each prefilled syringe contains enoxaparin sodium 15,000 IU anti-Xa activity (equivalent to 150 mg) in 1.0 mL water for injections. 
Ena napolnjena injekcijska brizga vsebuje 15.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 150 mg) v 1,0 ml vode za injekcije.
• The maximum amount of LOVENOX (and associated names) given for the first two injections is 7,500 IU (75 mg). 
• Največji odmerek zdravila LOVENOX (in povezana imena), uporabljen v prvih dveh injekcijah,
Multiple dose vials containing benzyl alcohol: 
Večodmerne viale, ki vsebujejo benzilalkohol:
STEMI enoxaparin sodium regimen was a 3,000 IU (30 mg) IV bolus followed by 100 IU/kg (1 mg/kg) SC every 12 hours. 
Intravenski bolus 3.000 i.e. (30 mg), ki mu je takoj sledila subkutana uporaba 100 i.e./kg (1 mg/kg) na
LOVENOX (and associated names) 2,000 IU (20 mg)/0.2 mL solution for injection LOVENOX (and associated names) 4,000 IU (40 mg)/0.4 mL solution for injection LOVENOX (and associated names) 6,000 IU (60 mg)/0.6 mL solution for injection LOVENOX (and associated names) 8,000 IU (80 mg)/0.8 mL solution for injection LOVENOX (and associated names) 10,000 IU (100 mg)/1 mL solution for injection 
- LOVENOX (in povezana imena) 2.000 i.e. (20 mg)/0,2 ml raztopina za injiciranje - LOVENOX (in povezana imena) 4.000 i.e. (40 mg)/0,4 ml raztopina za injiciranje - LOVENOX (in povezana imena) 6.000 i.e. (60 mg)/0,6 ml raztopina za injiciranje - LOVENOX (in povezana imena) 8.000 i.e. (80 mg)/0,8 ml raztopina za injiciranje - LOVENOX (in povezana imena) 10.000 i.e. (100 mg)/1 ml raztopina za injiciranje
In the clinical studies for treatment of unstable angina and non-Q-wave myocardial infarction, doses were 100 IU/kg (1 mg/kg) SC every 12 hours, and in the clinical study for treatment of acute 
V kliničnih študijah za zdravljenje nestabilne angine pektoris in miokardnega infarkta brez zobca Q so bili odmerki 100 i.e./kg (1 mg/kg)
If a manual compression method is used, sheath should be removed 6 hours after the last IV/SC enoxaparin sodium injection. 
morate ovojnico odstraniti 6 ur po zadnji intravenski/subkutani injekciji natrijevega enoksaparinata.
Careful clinical monitoring is advised and dose reduction might be considered in patients older than 75 years treated for STEMI (see sections 4.2 and 
75 let, zdravljenih zaradi STEMI, pride v poštev zmanjšanje odmerka (glejte poglavji 4.2 in 5.2).
Subcutaneous, intravenous use. 
subkutana, intravenska uporaba izventelesna uporaba (v dializnem obtoku)
Skin and subcutaneous tissue disorders 
Bolezni mišično-skeletnega sistema in vezivnega tkiva
Talk to your doctor or pharmacist before using LOVENOX (and associated names) if: 
Pred uporabo zdravila LOVENOX (in povezana imena) se posvetujte z zdravnikom ali farmacevtom:
LOVENOX (and associated names) 2,000 IU (20 mg)/0.2 mL solution for injection LOVENOX (and associated names) 4,000 IU (40 mg)/0.4 mL solution for injection LOVENOX (and associated names) 6,000 IU (60 mg)/0.6 mL solution for injection LOVENOX (and associated names) 8,000 IU (80 mg)/0.8 mL solution for injection LOVENOX (and associated names) 10,000 IU (100 mg)/1 mL solution for injection LOVENOX (and associated names) 30,000 IU (300 mg)/3 mL solution for injection LOVENOX(and associated names) 50,000 IU (500 mg)/5 mL solution for injection LOVENOX(and associated names) 100,000 IU (1,000 mg)/10 mL solution for injection LOVENOX (and associated names) 12,000 IU (120 mg)/0.8 mL solution for injection LOVENOX (and associated names) 15,000 IU (150 mg)/1 mL solution for injection 
LOVENOX (in povezana imena) 2.000 i.e. (20 mg)/0,2 ml raztopina za injiciranje LOVENOX (in povezana imena) 4.000 i.e. (40 mg)/0,4 ml raztopina za injiciranje LOVENOX (in povezana imena) 6.000 i.e. (60 mg)/0,6 ml raztopina za injiciranje LOVENOX (in povezana imena) 8.000 i.e. (80 mg)/0,8 ml raztopina za injiciranje LOVENOX (in povezana imena) 10.000 i.e. (100 mg)/1 ml raztopina za injiciranje LOVENOX (in povezana imena) 30.000 i.e. (300 mg)/3 ml raztopina za injiciranje LOVENOX (in povezana imena) 50.000 i.e. (500 mg)/5 ml raztopina za injiciranje LOVENOX (in povezana imena) 100.000 i.e. (1.000 mg)/10 ml raztopina za injiciranje LOVENOX (in povezana imena) 12.000 i.e. (120 mg)/0,8 ml raztopina za injiciranje LOVENOX (in povezana imena) 15.000 i.e. (150 mg)/1 ml raztopina za injiciranje
• Extended prophylaxis of venous thromboembolism (VTE) following orthopaedic surgery In a double blind study of extended prophylaxis for patients undergoing hip replacement surgery, 179 patients with no venous thromboembolic disease initially treated, while hospitalized, with enoxaparin sodium 4,000 IU (40 mg) SC, were randomized to a post-discharge regimen of either enoxaparin sodium 4,000 IU (40 mg) (n=90) once a day SC or to placebo (n=89) for 3 weeks. 
bolnikov brez venske trombembolične bolezni, ki so bili med hospitalizacijo uvodoma zdravljeni z natrijevim enoksaparinatom 4.000 i.e. (40 mg) subkutano, po odpustu za 3 tedne randomizirali na shemo z natrijevim enoksaparinatom 4.000 i.e. (40 mg) subkutano enkrat na dan (n = 90) ali na placebo (n = 89).
Each ampoule contains enoxaparin sodium 10,000 IU anti-Xa activity (equivalent to 100 mg) in 1.0 mL water for injections. 
Ena ampula vsebuje 10.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 100 mg) v 1,0 ml vode za injekcije.
LOVENOX (and associated names) 10 x 4,000 IU (10 x 40 mg) solution for injection [See Annex I - To be completed nationally] 
IME ZDRAVILA LOVENOX (in povezana imena) 10 x 4.000 i.e. (10 x 40 mg) raztopina za injiciranje
Package leaflet: Information for the user LOVENOX (and associated names) 10 x 4,000 IU (10 x 40 mg) doses solution for injection in a pen [See Annex I - To be completed nationally] enoxaparin sodium 
Navodilo za uporabo LOVENOX (in povezana imena) 10 x 4.000 i.e. (10 x 40 mg) odmerkov raztopina za injiciranje v peresniku
• Your doctor or nurse will normally give you LOVENOX (and associated names). 
• Običajno vam bo zdravilo LOVENOX (in povezana imena) dal zdravnik ali medicinska sestra.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION LOVENOX (and associated names) 10,000 IU (100 mg)/10 mL solution for injection [See Annex I - To be completed nationally] 
IME ZDRAVILA IN POT(I) UPORABE LOVENOX (in povezana imena) 10.000 i.e. (100 mg)/10 ml raztopina za injiciranje
Treatment of deep vein thrombosis with or without pulmonary embolism In a multicenter, parallel group study, 900 patients with acute lower extremity DVT with or without PE were randomized to an inpatient (hospital) treatment of either (i) enoxaparin sodium 150 IU/kg (1.5 mg/kg) once a day SC, (ii) enoxaparin sodium 100 IU/kg (1 mg/kg) every 12 hours SC, or (iii) heparin IV bolus (5,000 IU) followed by a continuous infusion (administered to achieve an aPTT of 55 to 85 seconds). 
Zdravljenje globoke venske tromboze, s pljučno embolijo ali brez nje V multicentrični študiji vzporednih skupin so 900 bolnikov z akutno GVT spodnje okončine, s PE ali brez nje, randomizirali na bolnišnično zdravljenje (i) z natrijevim enoksaparinatom 150 i.e./kg
Each prefilled syringe contains enoxaparin sodium 10,000 IU anti-Xa activity (equivalent to 100 mg) in 1.0 mL water for injections. 
Ena napolnjena injekcijska brizga vsebuje 10.000 i.e. aktivnosti anti-Xa natrijevega enoksaparinata (to ustreza 100 mg) v 1,0 ml vode za injekcije.
No IV initial bolus, 100 IU/kg (1 mg/kg) body weight SC and then 100 IU/kg (1 mg/kg) body weight SC every 24 hours 
(1 mg/kg) telesne mase subkutano, nato 100 i.e./kg (1 mg/kg) telesne mase subkutano na 24 ur
Prevention of thrombus formation during haemodialysis The recommended dose is 100 IU/kg (1 mg/kg) of enoxaparin sodium. 
Priporočeni odmerek je 100 i.e./kg (1 mg/kg) natrijevega enoksaparinata.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION LOVENOX (and associated names) 10,000 IU (100 mg)/1 mL solution for injection [See Annex I - To be completed nationally] enoxaparin 
IME ZDRAVILA IN POT(I) UPORABE LOVENOX (in povezana imena) 10.000 i.e. (100 mg)/1 ml raztopina za injiciranje
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER BOX MULTIDOSE VIAL 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA ZA PERESNIK
LOVENOX (and associated names) 12,000 IU (120 mg)/0.8 mL solution for injection LOVENOX (and associated names) 15,000 IU (150 mg)/1 mL solution for injection 
15.000 i.e./ml (150 mg/ml) raztopina za injiciranje: - LOVENOX (in povezana imena) 12.000 i.e. (120 mg)/0,8 ml raztopina za injiciranje - LOVENOX (in povezana imena) 15.000 i.e. (150 mg)/1 ml raztopina za injiciranje
NAME OF THE MEDICINAL PRODUCT LOVENOX (and associated names) 10,000 IU (100 mg)/10 mL solution for injection [See Annex I - To be completed nationally] Enoxaparin 
IME ZDRAVILA LOVENOX (in povezana imena) 10.000 i.e. (100 mg)/10 ml raztopina za injiciranje
LOVENOX (and associated names) 2,000 IU (20 mg)/0.2 mL solution for injection LOVENOX (and associated names) 4,000 IU (40 mg)/0.4 mL solution for injection LOVENOX (and associated names) 6,000 IU (60 mg)/0.6 mL solution for injection LOVENOX (and associated names) 8,000 IU (80 mg)/0.8 mL solution for injection LOVENOX (and associated names) 10,000 IU (100 mg)/1 mL solution for injection LOVENOX (and associated names) 12,000 IU (120 mg)/0.8 mL solution for injection LOVENOX (and associated names) 15,000 IU (150 mg)/1 mL solution for injection [See Annex I - To be completed nationally] 
LOVENOX (in povezana imena) 2.000 i.e. (20 mg)/0,2 ml raztopina za injiciranje LOVENOX (in povezana imena) 4.000 i.e. (40 mg)/0,4 ml raztopina za injiciranje LOVENOX (in povezana imena) 6.000 i.e. (60 mg)/0,6 ml raztopina za injiciranje LOVENOX (in povezana imena) 8.000 i.e. (80 mg)/0,8 ml raztopina za injiciranje LOVENOX (in povezana imena) 10.000 i.e. (100 mg)/1 ml raztopina za injiciranje LOVENOX (in povezana imena) 12.000 i.e. (120 mg)/0,8 ml raztopina za injiciranje LOVENOX (in povezana imena) 15.000 i.e. (150 mg)/1 ml raztopina za injiciranje [Glejte Prilogo I - Izpolni država članica]
Careful clinical monitoring is advised and dose reduction might be considered in patients older than 75 years treated for ST-segment elevation myocardial infarction (STEMI) (see section 5.2). 
75 let, zdravljenih zaradi STEMI, pride v poštev zmanjšanje odmerka (glejte poglavje 5.2).